Craig H. Moskowitz
Expertise in
12
conditions

Dr. Craig H. Moskowitz

Hematology
1425 Northwest 10th Avenue, 
Miami, FL 
Accepting New Patients
Offers Telehealth
38 Years of Experience
Expertise in
12
conditions
1425 Northwest 10th Avenue, 
Miami, FL 

Overview

Craig Moskowitz is a Hematologist practicing medicine in Miami, Florida. He has been practicing medicine for over 38 years.

Dr. Moskowitz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Non-Hodgkin Lymphoma.

He is actively involved in clinical research, co-authoring 151 peer reviewed articles and participating in 9 clinical trials. Dr. Moskowitz is currently accepting new patients.

Graduate Institution

Wayne State University - 1988

Residency

Jacobi Medical Center, Internal Medicine - 1992

Specialties

Hematology

Licenses

Internal Medicine in NY

Fellowships

Memorial Sloan-Kettering Cancer Center, Hematology/Oncology - 1995

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

1425 Northwest 10th Avenue, Miami, FL 33136
Other Locations
5555 Ponce De Leon Boulevard, Floor 4, Coral Gables, FL 33146

Additional Areas of Focus

Dr. Moskowitz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Follicular Lymphoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine
Study Phase: Not Applicable
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2, Open-Label Study of Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma
A Phase 2, Open-Label Study of Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma
Enrollment Status: Terminated
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Study Phase: Phase 2
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Procedure, Radiation, Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: October 26, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

151 Total Publications

Predictors and timing of venous thromboembolism and overall survival in lymphoma.
Predictors and timing of venous thromboembolism and overall survival in lymphoma.
Journal: Leukemia & lymphoma
Published: March 20, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
1475 Northwest 12th Avenue, 
Miami, FL 
 (0.1 miles away)
305-243-5302
Languages Spoken:
English, Hebrew, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Izidore Lossos is a Hematologist practicing medicine in Miami, Florida. Dr. Lossos is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Transplant. Dr. Lossos is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML). Dr. Sekeres is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Watts is a Hematologist practicing medicine in Miami, Florida. Dr. Watts is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Watts is currently accepting new patients.

Frequently Asked Questions about Dr. Craig H. Moskowitz

How do I make an appointment with Dr. Craig H. Moskowitz?

You can book an appointment with Dr. Craig H. Moskowitz by calling their office at 305-243-5302. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig H. Moskowitz a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig H. Moskowitz is classified as an Elite expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig H. Moskowitz specialize in?

While Dr. Craig H. Moskowitz is a Hematology, they have specific expertise in Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Craig H. Moskowitz participate in research or clinical trials?

Yes. Dr. Craig H. Moskowitz has published 151 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Craig H. Moskowitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig H. Moskowitz accept my insurance?

Dr. Craig H. Moskowitz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-5302 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moskowitz's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile